|
Showing 1 - 7 of
7 matches in All Departments
* Provides a one-stop text on the theoretical underpinning, and
application of, key sociological, psychological, philosophical and
behavioural economic disciplines to the study of human, in
particular consumer, behaviour. * The theories described in the
book are universal, straddling cultures and countries and making
the book truly international. * Written by a leading practitioner
in the field, with decades of practical experience.
* Provides a one-stop text on the theoretical underpinning, and
application of, key sociological, psychological, philosophical and
behavioural economic disciplines to the study of human, in
particular consumer, behaviour. * The theories described in the
book are universal, straddling cultures and countries and making
the book truly international. * Written by a leading practitioner
in the field, with decades of practical experience.
Perspectives on Anti-Inflammatory Drugs Inflammation is a very
complicated process of interrelated events and cas cades that does
not allow for an easily defined, focused attack for drug discovery.
It is evident from years of research and development that certain
classes of compounds (e.g., NSAIDs, steroids, and so on) have had a
meas ure of success in alleviating pain and even dampening
cellularlhormonal mechanisms involved in the process. Clear,
mechanism-related therapies (e.g., for arthritis) and targeted
drugs (e.g., for transplantation) have not been available in the
past and, in reality, research in inflammation has re lied on more
phenomenological approaches for resolving symptoms or on blatant
cytoreductive approaches in cases like organ transplantation. In
the last decade, approaches that have revealed novel cellular
pathways in which intervention is possible for lymphocyte
regulation (for example, cyclosporine and FK506) and small
molecular weight mediators (e.g., leu kotriene inhibitors) are now
either standard therapy or will be in a short time. These latter
approaches have been the result of research from the 1970s up to
the present."
A panel of leading academic and pharmaceutical investigators takes
stock of the remarkable work that has been accomplished to date
with proteasome inhibitors in cancer, and examines emerging
therapeutic possibilities. The topics range from a discussion of
the chemistry and cell biology of the proteasome and the rationale
for proteasome inhibitors in cancer to a review of current clinical
trials underway. The discussion of rationales for testing
proteasome inhibitors in cancer models covers the role of the
proteasome in NF-kB activation, the combining of conventional
chemotherapy and radiation with proteasome inhibition, notably
PS-341, new proteasome methods of inhibiting viral maturation, and
the role of protesome inhibition in the treatment of AIDS. The
authors also document the development of bortezomib (Velcade (TM))
in Phase I clinical trials and in a multicentered Phase II clinical
trials in patients with relapsed and refractory myeloma.
A panel of leading academic and pharmaceutical investigators takes
stock of the remarkable work that has been accomplished to date
with proteasome inhibitors in cancer, and examines emerging
therapeutic possibilities. The topics range from a discussion of
the chemistry and cell biology of the proteasome and the rationale
for proteasome inhibitors in cancer to a review of current clinical
trials underway. The discussion of rationales for testing
proteasome inhibitors in cancer models covers the role of the
proteasome in NF-kB activation, the combining of conventional
chemotherapy and radiation with proteasome inhibition, notably
PS-341, new proteasome methods of inhibiting viral maturation, and
the role of protesome inhibition in the treatment of AIDS. The
authors also document the development of bortezomib (Velcade (TM))
in Phase I clinical trials and in a multicentered Phase II clinical
trials in patients with relapsed and refractory myeloma.
|
You may like...
Higher
Michael Buble
CD
(1)
R172
Discovery Miles 1 720
|